Detection of prostate cancer using psa glycosylation patterns

11-21. (canceled)

A method of determining if a subject has prostate cancer, comprising:

• determining if a subject has an altered PSA α2,6-sialylation pattern as compared to the α2,6-sialylation pattern of PSA from a healthy subject;
• wherein an altered PSA α2,6-sialylation pattern is indicative of prostate cancer.

27-33. (canceled)

A method of determining if a subject has prostate cancer, comprising:

• determining if a subject has an altered PSA cc-2,3-sialylation pattern as compared to the α2,3-sialylation pattern of PSA from a healthy subject;
• wherein an altered PSA α2,3-sialylation pattern is indicative of prostate cancer.

35-45. (canceled)

A method for determining if a subject has cancer or benign prostate hyperplasia (BPH) comprising:

• determining if a subject has an altered PSA oc2,6-sialylation pattern as compared to the α2,6-sialylation pattern of PSA from a healthy subject;
• wherein an altered PSA α2,6-sialylation pattern is indicative of prostate cancer and a non-altered α2,6-sialylation pattern of PSA is indicative of benign prostate hyperplasia.

47-53. (canceled)

A method of determining if a subject has prostate cancer comprising:

• determining if a sample of PSA from a subject has increased levels of glycosylation with sialic acid, O-linked galactose or Man/GlcNAc with Fuca1-6 groups as compared to PSA from a healthy subject;
• wherein PSA with increased levels of glycosylation with sialic acid, O-linked galactose or Man/GlcNAc with Fuca1-6 groups as compared to PSA from a healthy subject is indicative of prostate cancer.

56-65. (canceled)

A kit for determining if a subject has prostate cancer comprising one or more lectins and a PSA specific antibody and instructions for use.

67-79. (canceled)